Medytox Inc.


Based on integrity and open communication, Medytox is building excellent capacity
and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies

메디톡스 정현호 대표이사

Message from the CEO of Medytox, Hyunho Jung

We are all ready to leap forward.

Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D.

Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc® and Meditoxin®), Medytox has shown a dramatic growth. Medytox reached nearly 40% of market share in Korea since 2009 and is expected to increase even further with various indications being included. The global botulinum toxin market continues to grow and is expected to further expand to not only medical aesthetics market but also therapeutic market. Medytox is stunning the world with high market share in the global botulinum market.
With the goal of penetrating to the US and Europe, we plan to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products. In the future, Medytox will grow as the leader of the biopharmaceutical industry by challenging ourselves with passion for the global market.
Name Medytox Inc.
Established May 2nd, 2000
CEO Hyunho Jung
Capital USD 3.4 million
Main Products Botulinum toxin product
Hyaluronic acid filler product
Domestic Medytox Building (Seoul)
R&D Center (Gwanggyo, Osong)
Medytox Plant I (Ochang)
Medytox Plant II (Osong)
Medytox Plant III (Osong)
Medytox Korea (Seoul, Busan, Daejeon, Daegu, and Gwangju)
International Medytox US Office (Maryland, USA)
Medybloom China (China joint venture)
Medytox Taiwan (Taiwan joint venture)
Medytox Hong Kong (Hong Kong joint venture)
Medytox Thailand (Thailand local subsidiary)
MDT International (Japan local subsidiary)